Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for Provoked Vestibulodynia
NCT02773641Phase 3Completed
- Sponsor
- Karolinska Institutet
- Start
- May 2016
- Primary completion
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in provoked vestibulodynia (PVD) (2 arms), sponsored by Karolinska Institutet. Primary endpoint: Self-reported dyspareunia at 24 weeks. Started May 2016; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
provoked vestibulodynia (PVD)
Beyond the preview
Go deeper on NCT02773641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02773641.